Skip to content
Screener

Aurinia Pharmaceuticals AUPH Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Kiniksa Pharmaceuticals International, plc logo
Kiniksa Pharmaceuticals International, plcKNSA
$24.72M+37.7%
ALN
Alnylam PharmaceuticalsALNY
$157.25M+368%

Other financials

Income statement

See full
Revenue$83.2M+18.9%
Gross profit$76.7M+21.9%
Operating income$46.3M+131%
Net income$37.4M+73.9%
EPS (diluted)$0.28+75.0%

Balance sheet

See full
Cash & equivalents$179.8M+239%
Total debt$80.6M-17.7%
Total equity$614.9M+83.4%
Total assets$792.3M+57.6%

Cash flow

See full
Operating cash flow$52.6M+18.8%

Valuation

See full
Market cap$2.11B+40.2%
Enterprise value$2.01B+29.7%
P/E6.7×-18.1×
P/S6.8×+1.0×

Profitability

See full
Gross margin90.4%+0.8pp
Operating margin48.4%+28.4pp
Net margin100.8%+77.5pp

Returns & leverage

See full
Return on equity66.1%+48.8pp
Debt / equity0.1×-0.2×
Current ratio5.4×+0.2×

Where this comes from

Reported directly by Aurinia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The source filing: Aurinia Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 8:16 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001600620-26-000062
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Net income$37,414$21,513$71,769$44,857
Other comprehensive income:
Unrealized loss on available-for-sale securities(97)(80)(378)(258)
Comprehensive income$37,317$21,433$71,391$44,599
Earnings per share
Basic$0.29$0.16$0.55$0.33
Diluted$0.28$0.16$0.53$0.32
Shares used in computing earnings per share

Item 1. Financial Statements.

FAQ

What is Aurinia Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent?
Aurinia Pharmaceuticals (AUPH) reported comprehensive income (loss), net of tax, attributable to parent of $37.32M in Q2 2026.
How has Aurinia Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Aurinia Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent increased by 74.1% year-over-year, from $21.43M to $37.32M.
What is the long-term trend for Aurinia Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent?
Over 4 years (2021 to 2025), Aurinia Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent has grown at a 12.2% compound annual growth rate (CAGR), from -$181.01M to $287.25M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This metric reflects the total change in equity from non-owner sources, including net income and other items that bypass the traditional income statement, such as unrealized gains or losses on investments and foreign currency translation adjustments. It provides a more holistic view of the company's financial performance and changes in net worth beyond standard operating results. Investors use this to assess the broader economic impact on the company's financial position that is not captured by net income alone.

Ask your AI about Aurinia Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude